 |
296 Diseases |  |
92 Trials |
|
92 Trials |  |
3449 News |  |
| «12...37383940414243444546474849» |
- | Victoza (liraglutide) / Novo Nordisk
New P4 trial: Trial for People With Established Type 2 Diabetes During Ramadan (clinicaltrials.gov) - Nov 17, 2014
P4, N=99, Completed, Sponsor: University of Leicester
- Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
Enrollment change, Trial termination, Trial primary completion date: Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis (clinicaltrials.gov) - Nov 14, 2014
P2, N=20, Terminated, Sponsor: Takeda
N=75 --> 20 | Recruiting --> Terminated | Trial primary completion date: Feb 2014 --> Sep 2014; Company decision; No safety or efficacy concerns (see detailed description)
- pioglitazone / Generic mfg.
Phase classification, IO biomarker: Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 14, 2014
P0, N=30, Terminated, Sponsor: National Cancer Institute (NCI)
N=75 --> 20 | Recruiting --> Terminated | Trial primary completion date: Feb 2014 --> Sep 2014; Company decision; No safety or efficacy concerns (see detailed description) Phase classification: P=N/A --> P0
- pioglitazone / Generic mfg.
Trial completion: Inflammation and Insulin Resistance in Rheumatoid Arthritis (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=34, Completed, Sponsor: Vanderbilt University
Phase classification: P=N/A --> P0 Active, not recruiting --> Completed
- | pioglitazone / Generic mfg.
Enrollment change: Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes (clinicaltrials.gov) - Nov 12, 2014
P3, N=30, Completed, Sponsor: University of Miami
Active, not recruiting --> Completed N=45 --> 30
- |||||||||| pioglitazone SR (AD-4833 SR) / Takeda, Zinfandel
New P3 trial: AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease (clinicaltrials.gov) - Nov 6, 2014
P3, N=316, Not yet recruiting, Sponsor: Takeda
- pioglitazone / Generic mfg.
Trial primary completion date: VA NASH: Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment (clinicaltrials.gov) - Oct 30, 2014
P4, N=90, Recruiting, Sponsor: Department of Veterans Affairs
N=45 --> 30 Trial primary completion date: Dec 2014 --> Jun 2016
- Kineret (anakinra) / SOBI
New P2 trial: INSPIRED: Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2 (clinicaltrials.gov) - Oct 30, 2014
P2, N=45, Recruiting, Sponsor: Department of Veterans Affairs
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical: Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers (clinicaltrials.gov) - Oct 28, 2014
P1, N=20, Completed, Sponsor: Boehringer Ingelheim
- losartan / Generic mfg., pioglitazone / Generic mfg.
Enrollment change, Combination therapy: Pioglitazone and Losartan Provides Additional Renoprotection (clinicaltrials.gov) - Oct 27, 2014
P=N/A, N=60, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Dec 2014 --> Jun 2016 N=35 --> 60
- micronized fenofibrate / Generic mfg., pioglitazone / Generic mfg., fenofibrate / Generic mfg.
Enrollment change, Trial termination: Insulin Resistance in Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Oct 20, 2014
P=N/A, N=11, Terminated, Sponsor: Department of Veterans Affairs
N=48 --> 11 | Active, not recruiting --> Terminated; Low recruitment in intervention study. Baseline data published.
- | pioglitazone / Generic mfg.
Enrollment change: Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome (clinicaltrials.gov) - Oct 17, 2014
P2, N=23, Completed, Sponsor: Joseph Calabrese, MD
Baseline data published. N=40 --> 23
- || Lipaglyn (saroglitazar) / Zydus Cadila
New P3 trial: GLAZED: A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease (clinicaltrials.gov) - Oct 17, 2014
P3, N=100, Recruiting, Sponsor: Command Hospital, India
- | pioglitazone / Generic mfg.
Enrollment change: Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance (clinicaltrials.gov) - Oct 17, 2014
P4, N=34, Completed, Sponsor: University Hospital Case Medical Center
N=40 --> 23 N=50 --> 34
- ||| pioglitazone / Generic mfg.
Enrollment closed, Trial primary completion date: Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy (clinicaltrials.gov) - Oct 17, 2014
P4, N=310, Active, not recruiting, Sponsor: Takeda
N=50 --> 34 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Sep 2015
- pioglitazone / Generic mfg.
Trial primary completion date: Pioglitazone for the Treatment of Bipolar Depression (clinicaltrials.gov) - Oct 15, 2014
P4, N=80, Recruiting, Sponsor: University Hospital Case Medical Center
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Sep 2015 Trial primary completion date: May 2014 --> May 2015
- pioglitazone / Generic mfg., quetiapine extended-release / Generic mfg.
Biomarker, Trial primary completion date: Pioglitazone and Quetiapine XR Pharmacogenetic Study (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=310, Enrolling by invitation, Sponsor: Joseph Calabrese, MD
Trial primary completion date: May 2014 --> May 2015 Trial primary completion date: May 2012 --> May 2015
- pioglitazone / Generic mfg.
Trial completion, Trial primary completion date: Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 2, 2014
P4, N=30, Completed, Sponsor: National Heart Institute, Mexico
Trial primary completion date: May 2012 --> May 2015 Active, not recruiting --> Completed | Trial primary completion date: Jan 2011 --> Jan 2012
- pioglitazone / Generic mfg.
Enrollment closed, Trial primary completion date: Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors (clinicaltrials.gov) - Oct 2, 2014
P1, N=100, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed | Trial primary completion date: Jan 2011 --> Jan 2012 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2012 --> Sep 2014
- | atorvastatin / Generic mfg., pioglitazone / Generic mfg.
Enrollment change: ARREST PAD (Peripheral Arterial Disease) (clinicaltrials.gov) - Sep 30, 2014
P2/3, N=76, Completed, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2012 --> Sep 2014 N=113 --> 76
- ||| pioglitazone / Generic mfg.
Trial completion: Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment" (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=1067, Completed, Sponsor: Takeda
N=113 --> 76 Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer
New P1 trial: Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991) (clinicaltrials.gov) - Aug 21, 2014
P1, N=28, Not yet recruiting, Sponsor: Pfizer
- ||| pioglitazone/glimepiride / Generic mfg., pioglitazone / Generic mfg.
Trial completion: Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=294, Completed, Sponsor: Takeda
Active, not recruiting --> Completed Active, not recruiting --> Completed
- pioglitazone / Generic mfg.
Enrollment change, Trial termination: Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=36, Terminated, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed N=66 --> 36 | Active, not recruiting --> Terminated; Lack of recruitment
- ||||| insulin peglispro (LY2605541) / Eli Lilly
Enrollment closed, Combination therapy: A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment (clinicaltrials.gov) - Jul 23, 2014
P3, N=380, Active, not recruiting, Sponsor: Eli Lilly and Company
N=66 --> 36 | Active, not recruiting --> Terminated; Lack of recruitment Recruiting --> Active, not recruiting
- | pioglitazone / Generic mfg.
New P2 trial: Neuroprotection of Pioglitazone in Acute Ischemic Stroke (clinicaltrials.gov) - Jul 21, 2014
P2, N=152, Recruiting, Sponsor: Taipei Medical University Shuang Ho Hospital
- pioglitazone / Generic mfg.
Trial primary completion date, IO biomarker: Pioglitazone for Oral Premalignant Lesions (clinicaltrials.gov) - Jul 10, 2014
P2b, N=100, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Mar 2014
- pioglitazone / Generic mfg.
Trial completion, Trial primary completion date, IO biomarker: Pioglitazone for Oral Premalignant Lesions (clinicaltrials.gov) - Jul 10, 2014
P2b, N=100, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2014 --> Mar 2014 Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Mar 2014
- ||| pioglitazone / Generic mfg.
Clinical: Pioglitazone Tablets Specified Drug-use Survey (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=246, Completed, Sponsor: Takeda
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
New P1 trial: Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers (clinicaltrials.gov) - Jul 8, 2014
P1, N=20, Completed, Sponsor: Boehringer Ingelheim
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical: Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers (clinicaltrials.gov) - Jun 26, 2014
P1, N=20, Completed, Sponsor: Boehringer Ingelheim
- ||||| pioglitazone / Generic mfg.
Enrollment closed: IRIS: Insulin Resistance Intervention After Stroke Trial (clinicaltrials.gov) - Jun 26, 2014
P3, N=3936, Active, not recruiting, Sponsor: Yale University
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Mar 2014 Recruiting --> Active, not recruiting
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical: Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers (clinicaltrials.gov) - Jun 26, 2014
P1, N=20, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- metformin / Generic mfg., pioglitazone / Generic mfg.
Trial primary completion date: TOSCA IT: Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial (clinicaltrials.gov) - Jun 22, 2014
P4, N=3371, Active, not recruiting, Sponsor: Italian Society of Diabetology
Not yet recruiting --> Completed Trial primary completion date: Jun 2013 --> Dec 2018
- metformin / Generic mfg., pioglitazone / Generic mfg.
Enrollment closed, Trial primary completion date: TOSCA IT: Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial (clinicaltrials.gov) - Jun 22, 2014
P4, N=3371, Active, not recruiting, Sponsor: Italian Society of Diabetology
Trial primary completion date: Jun 2013 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Dec 2018
- pioglitazone / Generic mfg.
Trial completion: Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone (clinicaltrials.gov) - May 9, 2014
P1, N=3, Completed, Sponsor: Royan Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Dec 2018 Recruiting --> Completed
- metformin / Generic mfg.
Clinical: ZODIAC-39: Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin. (clinicaltrials.gov) - May 5, 2014
P=N/A, N=4000, Recruiting, Sponsor: Medical Research Foundation, The Netherlands
- pioglitazone / Generic mfg.
Enrollment change: Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia (clinicaltrials.gov) - May 4, 2014
P2a, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=21 --> 33
- rosiglitazone / Generic mfg.
Enrollment change, FDG PET: Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging (clinicaltrials.gov) - Apr 21, 2014
P0, N=39, Completed, Sponsor: Washington University School of Medicine
N=21 --> 33 N=29 --> 39
- rosiglitazone / Generic mfg.
Trial completion, FDG PET: Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging (clinicaltrials.gov) - Apr 21, 2014
P0, N=39, Completed, Sponsor: Washington University School of Medicine
N=29 --> 39 Recruiting --> Completed
- pioglitazone / Generic mfg.
Enrollment closed, IO biomarker: Pioglitazone for Oral Premalignant Lesions (clinicaltrials.gov) - Apr 6, 2014
P2b, N=100, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| pioglitazone/glimepiride / Generic mfg., pioglitazone / Generic mfg.
Clinical: Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone (clinicaltrials.gov) - Mar 26, 2014
P=N/A, N=294, Active, not recruiting, Sponsor: Takeda
- || pioglitazone / Generic mfg.
Trial completion: Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes (clinicaltrials.gov) - Mar 3, 2014
P3, N=45, Completed, Sponsor: University of Miami
Recruiting --> Active, not recruiting Recruiting --> Completed
- pioglitazone / Generic mfg.
Trial completion: The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT) (clinicaltrials.gov) - Feb 28, 2014
P4, N=94, Completed, Sponsor: Korea University Anam Hospital
Recruiting --> Completed Recruiting --> Completed
- ||||||| pioglitazone / Generic mfg.
Trial completion: Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes (clinicaltrials.gov) - Feb 22, 2014
P3, N=1440, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed No longer recruiting --> Completed
- ||||||| vildagliptin / Generic mfg., pioglitazone / Generic mfg.
Trial completion, Combination therapy: Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes (clinicaltrials.gov) - Feb 22, 2014
P3, N=362, Completed, Sponsor: Novartis Pharmaceuticals
No longer recruiting --> Completed No longer recruiting --> Completed
- | pioglitazone / Generic mfg.
Trial completion: Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) (clinicaltrials.gov) - Feb 22, 2014
P3, N=247, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | pioglitazone / Generic mfg.
Trial completion: Treating Nonalcoholic Steatohepatitis With Pioglitazone (clinicaltrials.gov) - Feb 22, 2014
P2, N=18, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Action to Control Cardiovascular Risk in Diabetes (ACCORD) (clinicaltrials.gov) - Feb 6, 2014
P3, N=10251, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- pioglitazone / Generic mfg.
Enrollment change: Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma) (clinicaltrials.gov) - Dec 2, 2013
P2, N=20, Completed, Sponsor: University of Vermont
Active, not recruiting --> Completed N=40 --> 20